Codexis, Inc. logo CDXS - Codexis, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 9
HOLD 5
SELL 0
STRONG
SELL 0
| PRICE TARGET: $8.00 DETAILS
HIGH: $11.00
LOW: $5.00
MEDIAN: $8.00
CONSENSUS: $8.00
UPSIDE: 488.24%

Stock News

Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA

Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA

REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis , Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform.

Sep 28, 2026 02:00 AM • globenewswire.com
Analyzing Codexis (NASDAQ:CDXS) and Mettler-Toledo International (NYSE:MTD)

Analyzing Codexis (NASDAQ:CDXS) and Mettler-Toledo International (NYSE:MTD)

Mettler-Toledo International (NYSE: MTD - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations. Volatility and Risk Mettler-Toledo International has a beta of

Sep 23, 2026 10:28 PM • defenseworld.net
Codexis Reports Second Quarter 2026 Financial Results

Codexis Reports Second Quarter 2026 Financial Results

Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA Completed successful equity capital raise of approximately $25 million in net proceeds REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.

Aug 11, 2026 12:05 PM • globenewswire.com
Codexis: ECO Synthesis And Runway Reset Warrant An Upgrade (Rating Upgrade)

Codexis: ECO Synthesis And Runway Reset Warrant An Upgrade (Rating Upgrade)

CDXS is now shifting toward differentiated enzymes and ECO Synthesis, which I think could pay off as commoditized small molecules become less attractive. We've now seen a customer manufacturing order, as well as CDMO evaluations that validate there's interest in CDXS's offerings. However, I concede that this bull case remains inherently speculative until we see recurring commercial demand or larger contracts.

Jul 26, 2026 04:15 AM • seekingalpha.com
Codexis Announces Pricing of Public Offering of Common Stock

Codexis Announces Pricing of Public Offering of Common Stock

REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $1.50 per share. Net proceeds to Codexis from the offering are expected to be approximately $23.1 million after underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on or about July 27, 2026, subject to customary closing conditions. Codexis has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 2,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Jul 23, 2026 07:47 PM • globenewswire.com
Codexis Announces Proposed Public Offering of Common Stock

Codexis Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Codexis. In addition, Codexis intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the size or terms of the offering.

Jul 23, 2026 12:13 PM • globenewswire.com
Codexis Reports First Quarter 2026 Financial Results

Codexis Reports First Quarter 2026 Financial Results

Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities REDWOOD CITY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.

May 07, 2026 12:05 PM • globenewswire.com

Price Targets